Capella

03 Sep, 2020 RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis

On September 3, 2020, we hosted an online RNAi Roundtable to review progress with patisiran and vutrisiran, RNAi therapeutics in development for the treatment of transthyretin-mediated amyloidosis. Of note, we announced we have obtained clinical pharmacology data supporting the potential for a biannual subcutaneous dosing regimen option for vutrisiran, providing further product differentiation as a potential best-in-class agent, and discussed new clinical data presented at the European Society of Cardiology 2020 Congress providing further evidence that treatment with patisiran may lead to substantial reduction in cardiac amyloid burden in ATTR amyloidosis.

Read the press release
Access the replay
View the presentation
Read the transcript

29 Aug, 2020 New Results for GIVLAARI® (givosiran) at The Digital International Liver Congress™ 2020

During The Digital International Liver Congress™ 2020, we shared new interim data from the Phase 1/2 open-label extension (OLE) study of GIVLAARI^® (givosiran) in acute hepatic porphyria (AHP), as well as encore 12-month interim data from the OLE period of the ENVISION Phase 3 study of GIVLAARI.

Stein, et al. – “A Phase 1/2 Open-Label Extension Study of Givosiran, an Investigational RNAi Therapeutic, in Patients with Acute Intermittent Porphyria”
View the 12-month ENVISION OLE results

20 Aug, 2020 Nonclinical Research on Pharmacodynamic Durability of GalNAc-siRNA Conjugates Published in “Nucleic Acids Research”

We published nonclinical research describing the durability of gene silencing by GalNAc-conjugated siRNAs. The article, titled, “Investigating the Pharmacodynamic Durability of GalNAc-siRNA Conjugates,” was selected as a Breakthrough Paper by Nucleic Acids Research.

Read the press release
Read the paper in Nucleic Acids Research

10 Aug, 2020 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1

On August 10, 2020, we hosted an online RNAi Roundtable to review progress with lumasiran, an RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1.

Access the replay
View the presentation
Read the transcript

17 Jul, 2020 RNAi Roundtable: Early Stage RNAi Therapeutics Pipeline

On July 17, 2020, we hosted an online RNAi Roundtable to review progress in our early stage RNAi therapeutics pipeline.

Access the replay
View the presentation
Read the transcript

10 Jul, 2020 New Results for ONPATTRO (patisiran) at 2020 PNS Annual Meeting

New results and analyses of study data for ONPATTRO® (patisiran) were presented at the 2020 Peripheral Nerve Society (PNS) Annual Meeting, held June 27-30 as a virtual event.

Adams, et al. – “Global Open-Label Extension: 24-Month Data of Patisiran in Patients with hATTR Amyloidosis”

Lin, et al. – “Evaluation of Patisiran with Concomitant or Prior Use of Transthyretin Stabilizers”

Peltier, et al. – “Impact of Patisiran on Activities of Daily Living and Functional Status in hATTR Amyloidosis”

Coelho, et al. – “Open-Label Study of Patisiran in Patients with hATTR Amyloidosis Post-Orthotopic Liver Transplant”

Ticau, et al. – “Neurofilament Light Chain May Serve as a Biomarker in Hereditary Transthyretin-Mediated Amyloidosis”

30 Jun, 2020 New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria

Interim results from the open-label extension (OLE) period of the ENVISION Phase 3 study of GIVLAARI^® (givosiran) in acute hepatic porphyria (AHP) were presented by study investigator Eliane Sardh, M.D., Ph.D. during a webinar hosted by Alnylam, demonstrating sustained efficacy and acceptable safety through 12 months of treatment, with evidence for potentially improved efficacy over time.

Read our press release

View the presentation

View the webinar
 

23 Jun, 2020 RNAi Roundtable: ALN-AGT, in Development for the Treatment of Hypertension

On June 23, 2020, we hosted an online RNAi Roundtable to review the progress with ALN-AGT, an RNAi therapeutic in development for the treatment of hypertension.

Access the replay
View the presentation
Read the transcript

19 Jun, 2020 New Positive Results for Fitusiran Presented at WFH

New positive results from an interim analysis of the Phase 2 open-label extension (OLE) study of fitusiran, in development for the treatment of hemophilia A or B, with or without inhibitors, were presented at the World Federation of Hemophilia (WFH) Virtual Summit, held June 14-19, 2020.

View the presentation

18 Jun, 2020 Seventh Annual RNAi Roundtable Series

We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as clinical collaborators, will review recent progress in many of our pipeline programs and platform.